Wikileaks...more light, less clarity
This article was originally published in Scrip
With the possibility of getting a glimpse of some juicy insights into the machinations that take place in the corridors of power across the globe, it is hardly surprising that the Wikileaks publication of intra- and intergovernmental communications attracted a lot of media attention. Indeed, our coverage of what was being said in diplomatic channels about the dispute between Pfizer and the Nigerian government over a 1996 clinical trial in which 11 children died, was one of the most avidly read items on the Scrip website in the past week.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.